MedTrace Logo

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

NCT05590416 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-07-03

No results posted yet for this study

Summary

This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease

Conditions

Interventions

DRUG

Adalimumab

Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.

Sponsors & Collaborators

  • Tianjin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-12-01
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590416 on ClinicalTrials.gov